Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342119 · ClinicalTrials.gov registry record · NA
Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 1,315
- Enrollment target
NCT02342119: Completed NA study, sponsored by University of Pittsburgh.
NCT02342119 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 1,315 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02342119, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,315 participants
- Enrollment target
Study Summary
Living donor kidney transplantation (LDKT) is the optimal treatment for end-stage kidney disease (ESKD). But, the evaluation process for a kidney transplant is lengthy, time consuming, and burdensome to the patient. Also, race disparities exist in rates of transplant evaluation completion, transplantation, and LDKT. Our previous and ongoing NIDDK-funded research indicates that cultural factors (i.e., perceived discrimination in health care, religious objection to LDKT), transplant knowledge, and demographic characteristics (e.g., age, education, income) independently and significantly predict time to complete transplant evaluation. In December 2012 the investigators' transplant center implemented a one-day streamlined evaluation process, dubbed Kidney Transplant Fast Track (KTFT), but it has not been evaluated for efficacy or cost effectiveness. Thus, the investigators propose a quasi-experiment to determine the efficacy and cost-effectiveness of the KTFT (n=1030) compared to historical controls (n=1140) who were recruited for the investigators' current NIDDK study to increase transplant rates. At the same time, the investigators will conduct a randomized controlled trial (RCT) targeting vulnerable patients with the educational component of the TALK intervention (Talking About Live Kidney Donation) to increase LDKT. For both components of the proposal, the investigators will target vulnerable populations because they are most at risk for extended evaluation times and lower rates of LDKT. Using CONSORT standards, participants will be randomly assigned to TALK (n=515) versus no-TALK (n=515) conditions and undergo two interviews at pre-transplant work-up and at completion of transplant evaluation in order to: (1) test whether KTFT and TALK will reduce transplant evaluation time, and increase rates of transplant and LDKT in members of vulnerable groups; (2) determine whether engaging in a streamlined and coordinated-care evaluation experience within the transplant cente
Primary Outcome
This measure will assess whether or not the patient receives a kidney transplant
Interventions
- OTHER Talking About Living Kidney Donation
- OTHER Kidney Transplant Fast Track
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,315 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2020-08 |
| Phase | NA |
What the finished NCT02342119 record still lists
NCT02342119 is an interventional study that assigns participants to a tested intervention. Its 1,315 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Talking About Living Kidney Donation is the first listed.
NCT02342119 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02342119 about?
NCT02342119 is a clinical study titled "Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation". Living donor kidney transplantation (LDKT) is the optimal treatment for end-stage kidney disease (ESKD). But, the evaluation process for a kidney transplant is lengthy, time consuming, and burdensome to the patient. Also, race disparities exist in rates of transplant evaluation completion, transplan...
What is the current status of trial NCT02342119?
This trial is currently completed. It is a NA study. The enrollment target is 1,315 participants. The study started on 2015-05-01. Estimated completion is 2020-08.
What interventions are being tested in trial NCT02342119?
The interventions under investigation include: Talking About Living Kidney Donation (OTHER), Kidney Transplant Fast Track (OTHER).
Who is sponsoring clinical trial NCT02342119?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02342119's enrollment target sits among peer trials
1,315 76th of 2000 higher than 1,925 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05762302 · 1,316 participants · NA
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI